Sterile injectable formulations intended for parenteral administration in food-producing bovine and porcine species are prepared from gentamicin sulfate meeting the USP monograph potency of not less than 590 µg gentamicin base per milligram of dried substance; the salt correction factor at this potency is 1.694, such that a 50 mg gentamicin base per millilitre solution requires 84.7 mg of dried gentamicin sulfate per millilitre before reconciliation of assay overage is considered. Compliance for the finished injection is anchored in USP <71>, Ph. Eur. 2.6.1, USP <85>, Ph. Eur. 2.6.14, USP <788>, and Ph. Eur. 2.9.19 for sterility, bacterial endotoxin, and subvisible particulate control. The veterinary approval pathway additionally requires residue compliance with European Union Regulation 37/2010 MRLs for gentamicin in bovine and porcine tissues. The solution is compounded in a closed stainless steel mixing vessel under nitrogen overlay to limit oxidation, pH is adjusted with dilute sulfuric acid to 3.5–5.5, and the solution is passed through a two-stage sterilising filtration train consisting of a 0.45 µm PVDF prefilter and a 0.22 µm PVDF final filter. Filling into depyrogenated Type II glass vials is performed under ISO 5 laminar flow using a rotary piston pump; closure with bromobutyl rubber stoppers is followed by terminal steam sterilisation at 121°C for 15 min where site validation demonstrates an F0 of not less than 8 min. The injection must not be mixed in the same intravenous line with beta-lactam antibiotics because aminoglycoside inactivation through nucleophilic opening of the beta-lactam ring occurs at clinically relevant concentrations. Representative reference composition for a 50 mg base per millilitre solution is tabulated below.

Terminal finished product types are 50 mg base per millilitre in 50 mL and 100 mL vials and 100 mg base per millilitre in 100 mL and 250 mL bottles for large-animal use.

What limits drinking-water solubility during oral powder manufacture?

The limiting parameter for oral water-soluble powders is not the intrinsic aqueous solubility of gentamicin sulfate, which is classified as freely soluble in water by compendial solubility criteria, but rather the segregation-driven assay drift when the API is blended with a coarse mineral or sugar carrier. A 10.0% w/w gentamicin base intermediate is manufactured by geometric dilution of milled gentamicin sulfate with dextrose monohydrate, followed by tumble blending in a double-cone or V-blender at 10–20 rpm for 15 min and screening through an 850 µm sieve; packaging is conducted with RH below 40%. The field dilution of 1.0 kg of this intermediate per 1000 L of drinking water yields 100 ppm gentamicin base, which serves as the arithmetic bridge between formulation addition ratio and terminal dosing. Compliance rests on USP <61>, USP <62>, Ph. Eur. 5.1.4, and the relevant national approval with species-specific withdrawal periods; European Union Regulation 37/2010 classifies gentamicin with MRLs in bovine and porcine muscle and fat of 50 µg/kg, liver 200 µg/kg, kidney 750 µg/kg, and milk 100 µg/kg. Terminal finished product types include 100 g, 500 g, and 1 kg foil laminate sachets, along with 25 kg polyethylene-lined drums for farm-grade dispensing.

In medicated feed manufacture, feed premix granulation imposes a different stability boundary than water-soluble powders because the API is exposed to conditioner steam, pellet die friction, and post-drying moisture. A typical intermediate premix carrying 200 g gentamicin activity per kilogram on a soy-hull or lactose carrier is blended in a ribbon mixer at 15–25 rpm for 10–15 min after geometric preblending; low-shear granulation in a ploughshare mixer with a 2% w/w hydroxypropyl methylcellulose binder solution is used when dust suppression is required. The granulated premix is sieved through an 850 µm mesh and dried until loss on drying is below 5%. Dilution of the granulated premix into complete feed at 0.5–1.0 kg/t yields 100–200 ppm gentamicin base, as shown below. Manufacture of medicated feed is governed by Regulation (EU) 2019/4 for medicated feed and, for the premix itself, by FAMI-QS or equivalent national feed safety assurance; residue compliance remains linked to European Union Regulation 37/2010 MRLs. When pelleted feed is produced, conditioners operating above 75°C require site-specific stability data because published degradation kinetics for gentamicin sulfate in feed matrices remain limited. Terminal finished product types are 25 kg multi-wall paper bags with polyethylene inner liners of 100 g/kg or 200 g/kg premix and the resulting complete medicated meal or pellets for swine.

Ophthalmic isotonicity and preservative retention within 290–310 mOsm/kg

An ophthalmic solution containing gentamicin sulfate equivalent to 3 mg gentamicin base per millilitre is buffered to pH 6.5–7.5 with a phosphate buffer system and adjusted to 290–310 mOsm/kg using sodium chloride; benzalkonium chloride at 0.1 mg/mL serves as the preservative and disodium edetate at 0.5 mg/mL chelates trace metals that would otherwise destabilise the aminoglycoside. The solution is passed through a 0.22 µm sterilising-grade membrane and filled into low-density polyethylene dropper bottles under ISO 5 conditions; terminal autoclaving of LDPE bottles is avoided because polymer deformation and benzalkonium chloride adsorption onto hydrophobic bottle surfaces can reduce preservative availability. Compliance for ophthalmic products is governed by USP <771>, USP <51> for preservative efficacy, USP <71>, Ph. Eur. 5.1.1, Ph. Eur. 2.6.1, and Ph. Eur. 2.6.14; sterility and endotoxin limits follow the same compendial test designs as injectables. Preservative efficacy must meet the log-reduction criteria of USP <51> against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis. Terminal finished product types are 5 mL and 10 mL sterile ophthalmic dropper bottles for dogs, cats, horses, and zoo companion species.

When intramammary syringe fill weight and teat canal retention parameters intersect

Because the teat canal is a narrow, low-volume orifice, intramammary infusion products are filled into single-use low-density polyethylene syringes with a narrow-bore cannula; the fill weight is controlled to 8 mL or 10 mL per syringe, with a representative aqueous suspension containing 50 mg gentamicin base per syringe. Sterility is confirmed under USP <71> and Ph. Eur. 2.6.1, endotoxin under USP <85> and Ph. Eur. 2.6.14, preservative efficacy under USP <51>, and milk residue compliance is governed by the European Union Regulation 37/2010 MRL of 100 µg/kg for bovine milk. The vehicle is compounded in a closed vessel under low-bioburden conditions; if a high-viscosity suspending vehicle such as hydroxyethyl cellulose is used, high-shear mixing at 8,000 rpm for 10 min is applied to achieve dispersion, and fill weight verification is performed gravimetrically on-line. Terminal steam sterilisation is generally not used for thickened suspensions because heat can alter rheology and cause syringe-tip plugging; aseptic processing or gamma irradiation after final closure is used where validated. Rheological stability must be confirmed at 5°C storage because phase separation at low temperature can alter dose delivery from the cannula. Terminal finished product types are 8 mL and 10 mL single-dose intramammary syringes for lactating and dry cow formulations.

Oral tablet and capsule configurations for gentamicin sulfate are constrained by the negligible systemic absorption of aminoglycosides across the intact intestinal epithelium; published pharmacokinetic data describe an oral bioavailability below 1% in monogastric species. Consequently, oral solid dosage forms are positioned only for lumen-directed bacterial suppression in companion animals, and no harmonised USP or Ph. Eur. monograph currently defines a tablet or capsule composition. Compliance therefore falls to USP <795> for extemporaneous compounding or to 21 CFR 211 and USP <711> for a registered product where national approval allows such manufacture. The addition ratio is not fixed by a compendial monograph; the API mass per unit is derived from the prescribing veterinarian’s dose and the selected capsule size, typically accommodated through geometric dilution with lactose monohydrate. Direct compression tablets are prepared by blending gentamicin sulfate with microcrystalline cellulose, crospovidone, and magnesium stearate in a V-blender at 10–20 rpm for 15 min, followed by tableting; encapsulation uses a low-humidity environment below 40% RH to limit hygroscopicity-driven flow defects. Published data for commercial-scale oral solid dosage forms of gentamicin sulfate are limited, and systemic efficacy is not expected from oral administration. Terminal finished product types are hard gelatin capsules and film-coated tablets for gastrointestinal lumen-directed therapy in companion animal species.